Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness

Raffaella Bonecchi, Benedetta Savino, Nicoletta Caronni, Giuseppe Celesti, Alberto Mantovani, Massimo Locati

Research output: Contribution to journalArticlepeer-review


Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor microenvironment, unleashing accumulation of tumor-associated macrophages that sustains tumor growth. This discovery extends our understanding on the role of inflammatory chemokines in tumor biology and provides rationale for their therapeutic targeting.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
Issue number12
Publication statusPublished - Dec 2 2014


  • atypical chemokine receptors
  • chemokines
  • inflammation and cancer
  • Kaposi's sarcoma
  • macrophages

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness'. Together they form a unique fingerprint.

Cite this